HER2-POSITIVE METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets tough breast cancer
Disease control OngoingThis study tests a combination of two targeted drugs, tucatinib and alpelisib, in about 40 adults with a specific type of advanced breast cancer (HER2-positive with a PIK3CA mutation). The goal is to see if the combo is safe and can slow or stop tumor growth. Participants take bo…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New hope for advanced breast cancer: experimental drug ARX788 tested after other treatments fail
Disease control OngoingThis phase 2 study tests an experimental drug called ARX788 in 72 adults with HER2-positive metastatic breast cancer who have already been treated with a drug called T-DXd. The main goal is to see how many patients' tumors shrink or disappear. Participants must have measurable tu…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated May 26, 2026 11:44 UTC
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New drug cocktail targets breast cancer brain metastases
Disease control OngoingThis study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. The approach aims to improve…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Nancy Lin, MD • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
New imaging agent aims to spot HER2 cancers safely
Diagnosis OngoingThis early-stage study tests whether a new imaging drug called 89Zr-ss-pertuzumab is safe for people with HER2-positive cancers. About 60 adults with HER2-positive or HER2-low breast or other cancers will receive the agent and be monitored for side effects. The goal is to see if …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated May 19, 2026 12:01 UTC
-
Exercise test may spot heart risks in breast cancer patients
Knowledge-focused OngoingThis study looks at whether a cardiopulmonary exercise test (CPET) can help predict heart and lung function in women with HER2-positive breast cancer who have mild heart problems from their treatment. About 23 women will do a special exercise test to measure oxygen use. The goal …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 11:47 UTC